April 21st 2025
We preview several noteworthy P2 presentations in the urologic oncology space.
Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone
September 3rd 2024Panelists discuss how criteria such as patient comorbidities, disease progression levels, and treatment goals should be considered when selecting the appropriate form of abiraterone for patients with mCRPC, and also explore the potential benefits and drawbacks of using micronized abiraterone in specific patient populations.
The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies
September 3rd 2024Panelists discuss how the STAAR study (Stein, 2018) indicates that the micronized abiraterone formulation results in lower average serum testosterone levels in 25% of patients compared to 17% with the originator formulation, potentially influencing treatment selection.
Influences and Challenges of Biomarkers on Treatment Selection
August 30th 2024The key opinion leaders explore various treatment approaches for prostate cancer, including surgery, radiation, and hormone therapy, explaining how biomarker results influence their treatment choices. They also detail the specific criteria they use to select between treatment options based on biomarker testing outcomes.
Challenges in Risk Assessment and Biomarkers in Treatment Recommendations
August 30th 2024The panelists examine the challenges and limitations they've faced when using the Gleason score for risk assessment in prostate cancer patients, while also highlighting how biomarker testing has informed and guided their treatment strategies.
Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC
August 23rd 2024Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.
Motolani Adedipe, PhD, on a mobile app for Black men with prostate cancer
August 9th 2024"By helping them see what could be going on with their health and knowing when to reach out for help, we think that's a fantastic way to begin to change the paradigm when it comes to men and prostate cancer in the US," says Motolani Adedipe, PhD, DPh, MSc.